These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24828964)

  • 1. Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.
    Markowitz MA; Levitan BS; Mohamed AF; Johnson FR; Bridges JF; Alphs L; Citrome L
    Psychiatr Serv; 2014 Sep; 65(9):1133-9. PubMed ID: 24828964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
    Levitan B; Markowitz M; Mohamed AF; Johnson FR; Alphs L; Citrome L; Bridges JF
    Psychiatr Serv; 2015 Jul; 66(7):719-26. PubMed ID: 25772762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey.
    Kulkarni J; Reeve-Parker K
    Australas Psychiatry; 2015 Jun; 23(3):258-64. PubMed ID: 25783668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatrists' self-reported adherence to evidence-based prescribing practices in the treatment of schizophrenia.
    Young GJ; Mohr DC; Meterko M; Seibert MN; McGlynn G
    Psychiatr Serv; 2006 Jan; 57(1):130-2. PubMed ID: 16399975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric opinion and antipsychotic selection in the management of schizophrenia.
    Arbuckle MR; Gameroff MJ; Marcus SC; West JC; Wilk J; Olfson M
    Psychiatr Serv; 2008 May; 59(5):561-5. PubMed ID: 18451017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatrists' psychotropic drug prescription preferences for themselves or their family members.
    Latas M; Stojkovic T; Ralic T; Milovanovic S; Jasovic-Gasic M
    Psychiatr Danub; 2012 Jun; 24(2):182-7. PubMed ID: 22706417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
    Apiquian R; Fresán A; de la Fuente-Sandoval C; Ulloa RE; Nicolini H
    BMC Psychiatry; 2004 Apr; 4():12. PubMed ID: 15109398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding or switching antipsychotic medications in treatment-refractory schizophrenia.
    Kreyenbuhl J; Marcus SC; West JC; Wilk J; Olfson M
    Psychiatr Serv; 2007 Jul; 58(7):983-90. PubMed ID: 17602016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
    Katz EG; Hauber B; Gopal S; Fairchild A; Pugh A; Weinstein RB; Levitan BS
    Patient Prefer Adherence; 2016; 10():2127-2139. PubMed ID: 27799749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications.
    Llorca PM; Lançon C; Hartry A; Brown TM; DiBenedetti DB; Kamat SA; François C
    BMC Psychiatry; 2017 Feb; 17(1):67. PubMed ID: 28193195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
    Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication.
    Valenstein M; McCarthy JF; Ganoczy D; Bowersox NW; Dixon LB; Miller R; Visnic S; Slade EP
    Psychiatr Serv; 2013 May; 64(5):445-51, 451.e1. PubMed ID: 23412131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genderwise clinical response of antipsychotics among schizophrenic patients: a prospective observational study from Lahore, Pakistan.
    Asif U; Saleem Z; Yousaf M; Saeed H; Hashmi FK; Islam M; Hassali MA; Saleem F
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):177-183. PubMed ID: 29082784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How psychiatrists inform themselves and their patients about risks and benefits of antipsychotic treatment.
    Mendel R; Hamann J; Traut-Mattausch E; Jonas E; Heres S; Frey D; Kissling W
    Acta Psychiatr Scand; 2009 Aug; 120(2):112-9. PubMed ID: 19236315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.